Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


12 Nov 2016 - 16 Nov 2016
16 Nov 2016 - 19 Nov 2016

2013 JIB Congress to Emphasize New Perspectives in Medical Biology

By BiotechDaily International staff writers
Posted on 15 Jul 2013
Print article
A new governance has been set up to organize the next Journées Internationales de Biologie (JIB; Paris, France), its 58th annual meeting of medical biologists, to be held November 13–15, 2013 at the CNIT Paris, La Défense. In order to place the congress as a key "laboratory agenda" professional event, JIB renews itself not only as a recurring gathering for the profession, but also as an opportunity to gain fresh, positive perspectives on one's daily practice in the laboratory.

In order to optimize attendee presence at the meeting, efficiency is emphasized in enabling participants in each area to gather, individually or collectively, in a productive manner. Medical biologists can find solutions in various missions (HR, quality, logistics, finance, etc.) and fields (hematology, virology, biochemistry, etc.) by their participation in the congress, the exhibition, and the JIB Awards. Discussions and exchanges between specialists take place on the "Paroles d’Experts.” The "Institutions Corner" brings together various authorities for the profession (regional associations, societies, orders, ministries, syndicates, or humanitarians). JIB is also committed to the new generation and has dedicated the "Recruitment Sphere" section with practical workshops to help facilitate access and integration of new biologists to the professional world.

The exhibition platform for launching innovations will present nearly 200 technological advances and solutions, of which 75% have a European and worldwide scope, and 78% are presented for the first time. Innovation is particularly visible at the "Innovation Gallery," and is further emphasized at the JIB Awards ceremony, provided for the second time after its success in 2012, now with six new categories: Procedures Improvement, Innovation Gallery, Quality and Accreditation, Emergency Biology and POC, Post Analytics Innovation, and the Jury’s Award.

The congress sessions mainly relate to the multidisciplinary aspect of medical biology, innovative laboratory equipment and technologies, and the role of biology in healthcare policies and organization. The inaugural session “Medical biology and screening policies” highlights biology in preventive and individualized medicine as the desired alternative to curative medicine. The session on “Nanotechnologies, first outcomes and perspectives in medical biology” presents an overview of the miniaturized technologies that are transforming diagnosis and follow-up methods. In parallel to the scientific sessions, the "Colloquium" offers working sessions to assist with various topics such as laboratory services, the medical biology laboratory in local health policies, and the evolution of the biomedical practice organization.

Related Links:

JIB - Journées Internationales de Biologie

Print article


Drug Discovery

view channel
Image: Positive alpha-synuclein staining of a Lewy body from a patient with Parkinson\'s disease (Photo courtesy of Wikimedia Commons).

Bifunctional Dimer Drugs Prove Effective in Parkinson's Disease Yeast Model

A team of Canadian neurodegenerative disease researchers used a yeast model system to identify novel drug compounds that were able to block the misfolding of alpha- synuclein (AS) protein, which characterizes... Read more


view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more


view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.